Onasemnogen abeparvovec 166.00 Mrd., Onasemnogen abeparvovec 110.00 Mrd. in 5.5 ml Lsg. 8.3 ml Lsg. Infusionslösung St a 30.3 ml

Buyer

PBMG eG

Winners

Novartis Gene Therapies EU Ltd.

Contract value

no value published

Bids received

1

Published

2 Mar 2026

Awarded

29 Dec 2025

Contract start

1 Jan 2026

Contract end

31 Dec 2026stated

Sector

Medical equipment and pharmaceuticals

Region

Hamburg (DE600)

Source

Original notice on TED (147497-2026)

More awards from this buyer